{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:29Z","timestamp":1786988069017,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.115991","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T17:55:38Z","timestamp":1701280538000},"page":"115991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synthesis and biological evaluation of Ribo 7-N\/O\/S pyrimidine 9-deaza C-nucleoside analogs as new antiviral agents for inhibiting HCV RNA-dependent RNA polymerases"],"prefix":"10.1016","volume":"264","author":[{"given":"Minwan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Vadlakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"El-Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Hsing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanda","family":"Chambers-Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Bantia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Kellogg-Yelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooran","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.S.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-6506","authenticated-orcid":false,"given":"Pravin L.","family":"Kotian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115991_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2013.11.008","article-title":"Chutes and Ladders in hepatitis C nucleoside drug development","volume":"102","author":"Coats","year":"2014","journal-title":"Antivir. Res."},{"issue":"5B","key":"10.1016\/j.ejmech.2023.115991_bib3","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/hep.1840360707","article-title":"Fibrosis and disease progression in hepatitis C","volume":"36","author":"Marcellin","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115991_bib4","series-title":"Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection","author":"Who","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115991_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2893.2011.01526.x","article-title":"New developments in HCV therapy","volume":"1","author":"Kronenberger","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115991_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-0031-1297928","article-title":"The Era of direct-acting antivirals has begun: the beginning of the end for HCV?","volume":"31","author":"Vachon","year":"2011","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115991_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jgh.12028","article-title":"Current prospects for interferon-free treatment of hepatitis C in 2012: interferon-free hepatitis C virus treatment","volume":"28","author":"Stedman","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115991_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035759","article-title":"New details of HCV NS3\/4A proteinase functionality revealed by a high-throughput cleavage assay","volume":"7","author":"Shiryaev","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115991_bib9","first-page":"Doc08","article-title":"Protease inhibitors for the treatment of hepatitis C virus infection","volume":"5","author":"Leuw","year":"2017","journal-title":"Gms. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115991_bib10","series-title":"Clinical Trials","first-page":"635","article-title":"Chapter 29 - mechanisms of action\u2014Part IV (infections)","author":"Brody","year":"2016"},{"key":"10.1016\/j.ejmech.2023.115991_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/j.1460-2075.1996.tb00329.x","article-title":"Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"15","author":"Behrens","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2023.115991_bib12","first-page":"331","article-title":"Sofosbuvir: a novel oral agent for chronic hepatitis C","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Ann. Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2023.115991_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115991_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cld.2009.05.001","article-title":"HCV NS5B polymerase inhibitors","volume":"13","author":"Burton","year":"2009","journal-title":"Clin. Liver Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115991_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/13543770802672598","article-title":"Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection","volume":"19","author":"Beaulieu","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115991_bib16","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2\u2032-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115991_bib17","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1021\/jm030424e","article-title":"Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase","volume":"47","author":"Eldrup","year":"2004","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2023.115991_bib18","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1021\/jm040068f","article-title":"Structure-activity relationship of heterobase-modified 2\u2019-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication","volume":"47","author":"Eldrup","year":"2004","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2023.115991_bib19a","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/jm0701021","article-title":"Liver-targeted prodrugs of 2\u2019-C-methyladenosine for therapy of hepatitis C virus infection","volume":"50","author":"Hecker","year":"2007","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115991_bib19b","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jac\/dkp294","article-title":"FV100 as a new approach for the possible treatment of varicella-zoster virus infection","volume":"64","author":"McGuian","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"issue":"15","key":"10.1016\/j.ejmech.2023.115991_bib20","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1016\/j.bmc.2007.05.020","article-title":"Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2\u2019-C-methyladenosine","volume":"15","author":"Butora","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115991_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/nass\/nrn305","article-title":"Synthesis and study of 9-deazaguanosine derivatives as potential inhibitors of RNA virus replication","volume":"52","author":"Hamann","year":"2008","journal-title":"Nucl. Acid S"},{"key":"10.1016\/j.ejmech.2023.115991_bib22","article-title":"Synthesis and use of 2\u2019-substituted-N6-modified nucleosides as antiviral agents","volume":"1","author":"An","year":"2004","journal-title":"U. S. Patent WO 2004065398A3, January"},{"key":"10.1016\/j.ejmech.2023.115991_bib23","article-title":"2\u2019- and 3\u2019-nucleoside prodrugs for treating flaviviridae infections","volume":"8","author":"Sommadossi","year":"2004","journal-title":"U. S. Patent WO2004002999A2, January"},{"issue":"19","key":"10.1016\/j.ejmech.2023.115991_bib24","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/S0040-4020(00)00194-0","article-title":"Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases","volume":"56","author":"Evans","year":"2000","journal-title":"Tetrahedron"},{"issue":"21","key":"10.1016\/j.ejmech.2023.115991_bib25","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1021\/jm040068f","article-title":"Structure-activity relationship of heterobase-modified 2\u2019-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication","volume":"47","author":"Eldrup","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115991_bib26","article-title":"Nucleoside derivatives as antiviral agents and inhibitors of RNA-dependent RNA viral polymerase","author":"Carroll","year":"2012","journal-title":"U.S. Patent US 7105499B2"},{"key":"10.1016\/j.ejmech.2023.115991_bib27","series-title":"Methods of Inhibiting Orthopoxvirus Replication with Nucleoside Compounds","author":"Olsen","year":"2004"},{"key":"10.1016\/j.ejmech.2023.115991_bib28","first-page":"7316","article-title":"Synthesis of 1-O-Methyl-2-C-,\u03b2-Methyl-3,5-Bis-O-(2,4-Dichlorobenzyl)-\u03b1-D-Ribofuranose","volume":"37","author":"Leng","year":"2009","journal-title":"Anhui Nongye Kexue"},{"key":"10.1016\/j.ejmech.2023.115991_bib29","article-title":"Oligonucleotides having modified nucleoside units with various Linkages, and their uses as antisense agents, ribozymes, aptamers, SiRNA, probes, and primers, or when hybridized to RNA, as substrates for RNA cleaving enzymes","author":"Eldrup","year":"2003","journal-title":"U. S. Patent WO03099840A1"},{"key":"10.1016\/j.ejmech.2023.115991_bib30","article-title":"Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase","author":"Carroll","year":"2002","journal-title":"U. S. Patent WO2002057287"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115991_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"13","author":"Zein","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115991_bib32","first-page":"1131","article-title":"Strategies and mechanism in reversing intestinal drug efflux in oral drug delivery","volume":"14","author":"Lu","year":"2022","journal-title":"Pharm. Times"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115991_bib33","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1021\/acs.jmedchem.8b01263","article-title":"Clearance in drug design","volume":"62","author":"Smith","year":"2019","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115991_bib34","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","article-title":"Relevance of half-life in drug design","volume":"61","author":"Smith","year":"2018","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:06:20Z","timestamp":1759331180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423009583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"alternative-id":["S0223523423009583"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115991","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of Ribo 7-N\/O\/S pyrimidine 9-deaza C-nucleoside analogs as new antiviral agents for inhibiting HCV RNA-dependent RNA polymerases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115991"}}